Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2022-02-22 Share Issue/Capital Cha…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
ABS - Exercise of share options and issuance of shares
Share Issue/Capital Change Classification · 98% confidence The document explicitly details the exercise of share options by an outgoing CEO and the subsequent issuance of new shares by the Board of Directors, leading to an increase in the total number of outstanding shares. This directly relates to changes in the company's capital structure through the issuance of new stock. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general announcement of a report (RPA/RNS) as it contains substantive corporate action details, nor is it a Director's Dealing report (DIRS) which focuses on personal transactions, although this event is triggered by an executive action.
2022-02-22 English
Arctic Bioscience Operational Update Q4 2021
Earnings Release Classification · 99% confidence The document is titled "Arctic Bioscience Operational Update Q4 2021" and provides a detailed summary of financial results for the full year 2021 and Q4 2021, including revenue, EBITDA, cash position, and operational milestones (clinical trials, facility construction, management changes). This structure—comprehensive financial review for a period shorter than a full year (Q4/FY summary)—is characteristic of an Interim Report (IR). It is not a full Annual Report (10-K) as it covers only a specific fiscal period and is not explicitly labeled as such. It is too detailed to be just an Earnings Release (ER), which typically only contains highlights. Since it provides comprehensive period-specific financial details, IR is the most appropriate classification. Q4 2021
2022-02-18 English
Arctic Bioscience Operational Update Q4 2021
Earnings Release Classification · 99% confidence The document is titled "Arctic Bioscience Operational Update Q4 2021" and contains a summary of financial performance for the full year 2021 and Q4 2021, including revenue, EBITDA, CAPEX, and cash position. It also discusses operational milestones (psoriasis study, manufacturing facility) and management changes (new CEO appointed in January 2022, subsequent event). This structure—a comprehensive review of a fiscal period's operations and financials, often released shortly after the period ends—is characteristic of an Earnings Release (ER) or an Interim Report (IR). Since it covers the full year (FY 2021) but is presented as an 'Operational Update' summarizing key figures rather than a full, detailed statutory report (like a 10-K), it aligns best with an Earnings Release (ER) which provides the initial announcement of key results. If it were a comprehensive half-year report, it would be IR. Given the focus on Q4/FY highlights and outlook, ER is the most appropriate fit among the options provided, as it is not a full 10-K. Q4 2021
2022-02-18 English
Arctic Bioscience - CFO change
Board/Management Information Classification · 100% confidence The document explicitly announces a change in the Chief Financial Officer (CFO), stating that Danielle Glenn has terminated her consulting agreement and accepted a position elsewhere. This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in senior management. The filing type code for this is MANG.
2022-01-31 English
Arctic Bioscience - CFO change
Board/Management Information Classification · 99% confidence The document explicitly announces a change in the Chief Financial Officer (CFO), stating that Danielle Glenn has terminated her agreement and a search for a new permanent CFO has been initiated. This directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The content perfectly matches this description.
2022-01-31 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document text is titled 'Financial calendar' and lists key future dates for the company, including the release dates for the 'Half-yearly Report' and the 'Annual Report', as well as the date for the 'Annual General Meeting'. This document is not the report itself, but rather an announcement detailing the schedule of future corporate events and filings. Since it is an announcement about future reports and meetings, and does not fit the specific definitions for ER, IR, AGM-R, or 10-K (as it's a schedule, not the content), the most appropriate classification is Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it announces the publication dates of other reports, RPA is a strong candidate, but since it's a general calendar announcement, RNS (Regulatory Filings - general regulatory announcements) is also plausible. However, RPA specifically covers announcements regarding the timing/release of reports. Since the document's primary function is to announce the timing of reports, RPA is the best fit among the specific options, although RNS is the general fallback. Given the context of announcing future report publication dates, RPA is selected.
2022-01-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.